S&P 500
5.033,20 +14,81 (+0,30%) Nasdaq
15.708,34 +102,85 (+0,66%) NIKKEI 225
38.236,07 -37,98 (-0,10%) Dólar/Euro
1,0708 -0,0010 (-0,10%) Petróleo Brent
83,63 +0,19 (+0,23%) Bitcoin EUR
55.464,21 +2.147,30 (+4,03%)
Akari Therapeutics, Plc (AKTX)
Akari Therapeutics, Plc
22 Boston Wharf Road
Floor 7
Boston, MA 02210
United States
929 274 7510
https://www.akaritx.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 9
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Ms. Rachelle Suzanne Jacques | President, CEO & Director | 632,25k | N/A | 1971 |
| Ms. Melissa Bradford-Klug | Chief Operating Officer | N/A | N/A | 1970 |
| Dr. Miles Nunn | Chief Scientific Officer | N/A | N/A | 1969 |
| Dr. John F. Neylan III, M.D. | Executive VP & Chief Medical Officer | N/A | N/A | 1953 |
Descripción
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.
Gobierno corporativo
El ISS Governance QualityScore de Akari Therapeutics, Plc, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
